Drug profile · INN
ursodiol
URSODIOL
ursodiol (URSODIOL) is a bile acid receptor fxr agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — ursodiol
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 5
- Programs
- 8
- Data quality
- 0.89
Quick answer
ursodiol (URSODIOL) is a bile acid receptor fxr agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bile acid receptor FXR agonist
Primary target: Bile acid receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11583542
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11071742
Compositions for improving cell viability and methods of use thereof
granted -
US 10857162
Compositions for improving cell viability and methods of use thereof
granted -
US 10251896
Compositions for improving cell viability and methods of use thereof
granted -
US 9872865
Compositions for improving cell viability and methods of use thereof
granted
Frequently asked questions
What is ursodiol?
ursodiol (URSODIOL) is a bile acid receptor fxr agonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ursodiol?
URSODIOL is a marketed brand name for ursodiol. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ursodiol?
ursodiol has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.